Streetbeat News

Stock Prices

TSHA

14 analysts have provided mixed opinions on Taysha Gene Therapies (NASDAQ:TSHA) over the past quarter, with a majority being bullish or somewhat bullish. The average 12-month price target has increased to $6.79. Despite a decline in revenue and challenges in ROE and ROA, the company maintains a strong market position with a significant market capitalization.

Portfolio Pulse from Benzinga Insights

July 23, 2024 | 12:03 pm

FELE

Franklin Electric (NASDAQ:FELE) reported Q2 earnings per share of $1.26, missing the analyst estimate of $1.32. Sales were $543.26 million, also below the $569.91 million estimate. Both EPS and sales showed a decline compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:03 pm

PCAR

PACCAR (NASDAQ:PCAR) reported Q2 2024 earnings of $2.13 per share, missing the analyst estimate of $2.14. Sales were $8.262 billion, also below the $8.329 billion estimate. Both earnings and sales decreased compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:02 pm

CTSH

In the last three months, 9 analysts have published ratings on Cognizant Tech Solutions (NASDAQ:CTSH), with most being indifferent. The average 12-month price target has decreased by 3.39% to $77.89. Analysts' actions include raising, maintaining, and lowering ratings and price targets, reflecting mixed sentiments.

Portfolio Pulse from Benzinga Insights

July 23, 2024 | 12:01 pm

PODD

In the past three months, 7 analysts have provided ratings for Insulet (NASDAQ:PODD), ranging from bullish to bearish. The average 12-month price target is $225.14, with a high of $260.00 and a low of $200.00. Recent ratings include both raises and lowers in price targets, reflecting mixed sentiments.

Portfolio Pulse from Benzinga Insights

July 23, 2024 | 12:00 pm

ADIL

Adial Pharmaceuticals (NASDAQ:ADIL) has advanced to the second cohort in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. The study, which began in June 2024, is expected to conclude in Q4 2024, with topline results anticipated in the same quarter. The results will inform the design of a Phase 3 Clinical Trial.

Portfolio Pulse from Vandana Singh

July 23, 2024 | 12:00 pm

DNUT

Over the past three months, Krispy Kreme (NASDAQ:DNUT) has received mixed analyst ratings, with 3 bullish and 1 somewhat bullish ratings. The average 12-month price target is $14.75, down 7.81% from the prior average. Analysts have adjusted their price targets and ratings in response to market dynamics and company performance.

Portfolio Pulse from Benzinga Insights

July 23, 2024 | 12:00 pm

ADIL

Adial Pharmaceuticals has commenced patient dosing in the second cohort following the successful completion of the first cohort.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:00 pm

WMT

Jake Paul's personal care brand W has raised $14 million in seed and Series A funding, with a valuation north of $150 million. The brand, which launched exclusively in Walmart stores, aims to achieve $50 million in annual sales. The funding will support SKU and retailer expansion.

Portfolio Pulse from Chris Katje

July 23, 2024 | 12:00 pm

ADIL

Adial Pharmaceuticals has advanced to the second cohort in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. This progress marks a significant step in the development of the drug.

Portfolio Pulse from Benzinga Newsdesk

July 23, 2024 | 12:00 pm